Skip to content

NYMOX PHARMACEUTICAL CORPORATION

NYMXF

CIK 0001018735

← back to feed
Revenue (TTM)
$0
FY Dec 2024
Net Income (TTM)
−$13.76M
+49.2% YoY FY Dec 2024
EPS Diluted (TTM)
−$0.10
FY Dec 2024
Gross Margin
—
FY Dec 2024
Operating Margin
—
FY Dec 2024
Net Margin
—
FY Dec 2024
Free Cash Flow (TTM)
—
FY Dec 2024
Cash
$4.07M
FY Dec 2024
Total Debt
—
FY Dec 2024
Shares Outstanding
94.54M sh
FY Dec 2024

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings